A self-driven hypodermic injector that injects an injectable pharmaceutical composition at a constant baseline rate and may be manipulated to supplement the baseline rate with one or more pulses of the composition. The injector consists of a tubular housing with one fixed basal end wall that carries a hollow small gauge needle and one axially moveable end wall; an axially slideable water imbibing assembly mounted transversely in the housing lumen that divides the lumen into a pharmaceutical composition-containing compartment contiguous to the basal end wall and a water-containing compartment. In operation the subassembly imbibes water from the water-containing compartment and expands into the pharmaceutical-containing compartment to displace the pharmaceutical therefrom at the baseline rate. Pulses are effected by depressing the axially moveable end wall which in turn slides the subassembly toward the fixed end wall thereby exerting pressure on the pharmaceutical composition and increasing the injection rate.
|
1. A self-driven hypodermic injector for injecting an injectable pharmaceutical preparation into a patient according to a controlled dosage regimen comprising
(a) a hollow closed rigid body; (b) a water imbibing member mounted within the body that divides the lumen of the body into a first compartment adapted to hold the pharmaceutical preparation and a second compartment adapted to hold an aqueous liquid, the member comprising: (i) a rigid semipermeable wall that faces the second compartment; (ii) an expandable impermeable wall that faces the first compartment; and (iii) a water imbibing composition contained between the rigid semipermeable wall and the expandable impermeable wall; and (c) a conduit that extends through the wall of the body, one end of which opens into the first compartment and the other end of which is adapted to pierce the skin of the patient.
4. A self-driven hypodermic injector for injecting an injectable pharmaceutical preparation into a patient according to a controlled dosage regimen comprising:
(a) a rigid tubular housing have a pair of end walls that close the ends of the housing, one of the end walls providing a basal surface that is adapted to be placed against the skin of the patient; (b) a water imbibing member mounted transversely within the housing that divides the lumen of the housing into a first compartment that contains the pharmaceutical preparation and is contiguous to the housing end wall that provides said basal surface and a second compartment that contains water, the water imbibing member comprising (i) a rigid semipermeable wall that faces the second compartment; (ii) an expandable impermeable wall that faces the first compartment; and (iii) a water imbibing composition contained between the semipermeable wall and the impermeable wall; and (c) a hollow needle that extends from the first compartment through the housing end wall that provides the basal surface, one end of the needle opening into the first compartment and the other end of the needle being adapted to pierce the skin of the patient when the basal surface is placed against the skin of the patient.
2. The injector of
3. The injector of
(d) manually operable means for exerting a force on the member to cause it to slide within the body toward the first compartment.
5. The injector of
6. The injector of
(d) manually operable means for exerting a force on the water imbibing member to cause it to slide within the housing toward the end wall that provides the basal surface.
7. The hypodermic injector of
8. The hypodermic injector of
9. The hypodermic injector of
10. The hypodermic injector of
11. The hypodermic injector of
12. The hypodermic injector of
13. The hypodermic injector of
14. The hypodermic injector of
15. The injector of
16. The injector of
|
This invention relates to a self-driven hypodermic injector for administering an injectable pharmaceutical preparation to a patient according to a controlled dosage regimen.
The hypodermic syringe is perhaps the most common hypodermic injector. It consists of a barrel fitted with a plunger and a hollow needle. Mechanically driven syringes are employed to infuse drugs into patients continuously over relatively long periods.
U.S. Pat. Nos. 3,814,097, 3,964,482, and 4,159,720 disclose devices for administering drugs percutaneously on a continuous basis that include integral components that penetrate the skin. The latter employs wicks or monofilaments that are installed in the subcutaneous flesh and are connected to a drug reservoir attached to the skin surface. The drug is transported from the reservoir into the flesh by capillary action. The other two patents use hollow skin piercing projections that extend from the undersides of the respective devices.
A variety of osmotically driven fluid dispensers or injectors are either available commercially or described in the literature. These dispensers operate by imbibing water through a semipermeable membrane to displace fluid--typically a drug or other active agent--from the dispenser. Rose and Nelson, Austral. J. exp. Biol., 1955, 33, pp 415-420 describes one such injector. Its main components are a glass ampoule, two latex bags, and a semipermeable cellophane membrane mounted in a ring clamp. The ampoule has a nipple at one of its ends and a splayed mouth at the other end. One of the latex bags is partly collapsed, contains a saturated solution of Congo Red, and is tied over the clamp at a point below the bag mouth. This bag is placed in the ampoule with its edge tied over the splay of the ampoule mouth. The second bag is filled with water and its mouth is also tied over the splay of the ampoule mouth. Drug is contained in the space within the ampoule not occupied by the ring-first bag assembly. In operation, water is imbibed osmotically from the second bag through the cellophane member into the first bag causing the first bag to inflate. This inflation displaces drug from the ampoule via the nipple.
U.S. Pat. No. 3,604,417 describes another such injector which consists of three rigid chambers arranged in tandem. The first chamber contains the drug and has an outlet. The second contains a solution of an osmotically effective solute and is separated from the first by a piston. The third contains water and is separated from the second by a semipermeable membrane. In operation, water from the third chamber is imbibed through the semipermeable membrane into the second chamber due to an osmotic imbalance between the contents of the two chambers. The influx of water into the second chamber drives the piston that separates the second and first chambers into the first chamber, thereby displacing drug therefrom via the outlet.
U.S. Pat. No. 3,987,790 describes another type of osmotically driven dispenser. Its basic components are an inner flexible bag that contains the fluid to be dispensed, an intermediate layer of an osmotically effective composition that encapsulates the inner bag, an outer rigid semipermeable coating that encapsulates both the inner bag and intermediate layer, and an outlet/filling port that communicates with the interior of the inner bag. In operation the inner bag is charged with the fluid to be dispensed via the filling/discharge port and the dispenser is placed in an aqueous environment, such as a body cavity or within body tissue. Water is imbibed from the environment by the osmotically effective composition through the semipermeable coating into the space between the coating and the inner bag. Since the bag is flexible and the coating is rigid, the imbibed water squeezes the bag inwardly thereby displacing fluid from the bag via the discharge/filling port.
A principal object of the present invention is to provide a self-driven hypodermic injector that will inject a liquid pharmaceutical formulation into a patient at a constant controlled rate.
Another object of the present invention is to provide such an injector whose component parts align axially and thus may be assembled easily.
Yet another object of the present invention is to provide such an injector that includes means for supplementing the constant rate injection with one or more pulse injections of the pharmaceutical formulation.
The invention is a self-driven hypodermic injector that may be used to inject a pharmaceutical composition into a patient according to a controlled dosage regimen. The components of the injector are: (1) a hollow closed body; (2) a water-imbibing subassembly mounted within the body that divides the lumen of the body into two compartments one of which hold the pharmaceutical composition and the other of which holds an aqueous liquid and (3) a conduit, such as a hollow needle, that extends through the wall of the body into the pharmaceutical composition-containing compartment and is adapted to pierce the skin of the patient when the injector is placed against the skin. The water-imbibing assembly includes a rigid semipermeable wall that faces the water-containing compartment, an expandable impermeable wall that faces the pharmaceutical-containing compartment, and a water-imbibing composition sandwiched between the semipermeable and impermeable walls.
In the drawings, which are not to scale:
FIG. 1 is a perspective view of the preferred embodiment of the invention injector attached to the arm of a patient;
FIG. 2 is an exploded view of the injector of FIG. 1;
FIG. 3 is an enlarged sectional view of the injector of FIG. 1 taken along line 3--3 of FIG. 1;
FIG. 4 is an enlarged sectional view of another embodiment of the invention;
FIG. 5 is an enlarged sectional view of yet another embodiment of the invention; and
FIG. 6 is an enlarged sectional view of still another embodiment of the invention.
FIGS. 1-3 illustrate an injector, generally designated 11, that is capable of administering an injectable pharmaceutical composition 12 (FIG. 3) at a substantially constant rate with or without one or more manually instigated pulses. Injector 12 is cylindrical and is adapted to be placed on the patient's skin, such as on forearm 13, with one of its ends 14 defining a basal surface that rests against the skin. If need be, an adhesive overlay 15 or other affixation means may be employed to keep the injector positioned firmly on the skin.
The basic components of injector 11 and their axial relationship are shown in FIG. 2. Those components are: a cylindrical hollow housing 16 that includes integral end 14, has an internal shoulder 17, and is threaded on its inner surface near its open end 18; a hollow small gauge needle 19 that extends through end 14 to the lumen of the housing and projects normally outward from end 14; an axially slideable subassembly 22 that carries the water-imbibing means of the injector and is received within the lumen of the housing; a low friction washer 23 that is also received within the housing lumen; and an externally threaded end cap 24 that screws into the open end of the housing to close same. FIG. 3 shows these components in their assembled position with the injector charged with the fluids that make it operational.
As seen in FIG. 3, subassembly 22 divides the lumen of the housing into a first compartment 25 that is contiguous to end 14 and contains the pharmaceutical composition and a second compartment 26 that is contiguous to the end cap and contains an aqueous liquid 27. Subassembly 22 is slideably mounted within the housing by means of an O-ring 28 that is seated in a channel 29 formed in the exterior surface of the subassembly. The O-ring forms the principal seal between compartments 25 and 26 to prevent comtamination of the pharmaceutical composition by the aqueous liquid. Subassembly 22 is composed of an outer support ring 32 whose inner circumferential surface has a channel 33 and a trio of stepped shoulders 34, 35, 36 into and on which the other components of the subassembly are mounted. An elastomeric bellows-like impermeable bag 37 fits down through the central opening of the ring with its upper edge seated on shoulder 26. Bag 37 is filled with a water-imbibing composition 38. A disc of semipermeable membrane 39 extends across and closes the opening of bag 37 with its edge seated on shoulder 35. Finally, a locking washer 42 fits into channel 33 and seats on shoulder 34 to compress the edges of the bag and membrane.
Manually instigated axial movement of subassembly 22 toward end 14 is achieved through cooperative engagement between ring 32, washer 23, and end cap 24. Washer 23 is sandwiched between the top flat edge of the ring and the bottom flat edge of the end cap. It is the means by which rotation of the end cap is translated into axial movement of the subassembly. Specifically, such movement is effected by inserting a key or tool (not shown) into keyway 43 in the top of the end cap and twisting the end cap so that its screws into the housing. Since the washer surface is such that there is little friction between it and the end cap, the force component on the washer that is generated by twisting the cap is primarily axial. That force is in turn transmitted to the subassembly thereby driving it in piston-like fashion toward end 14 of the housing.
Injector 11 is used and operates as follows. Starting with the injector disassembled (as in FIG. 2), the pharmaceutical composition is charged into the housing lumen. Subassembly 22 is then inserted into the housing followed by the insertion of washer 23. The aqueous fluid is then charged into compartment 26 and the end cap is screwed into the open end of the housing. The thus assembled injector is then placed on the skin with needle 19 penetrating the cutaneous layer and end 14 lying substantially flush against the skin (FIGS. 1 and 3). As soon as the aqueous liquid is charged into compartment 26 water begins to be imbibed from compartment 26 through the semipermeable membrane into bag 37. Ambient pressure is maintained on the aqueous liquid by means of a vent 44 that extends through the end cap. The vent is filled with a material that is permeable to air but not permeable to water. Such imbibition is caused by an osmotic imbalance between the aqueous liquid and the composition 38. The influx of water into the bag causes the bag to expand (shown in phantom and indicated by the axially directed arrow in FIG. 3) into compartment 25 and thereby displace the composition therefrom via the needle to the injection site. The rate of water influx per unit area of semipermeable membrane will depend upon the composition and thickness of the membrane and the magnitude of the osmotic imbalance (this assumes insignificant back pressure from the bag). By keeping the osmotic imbalance substantially constant, the influx will be constant and so will the rate of injection of the pharmaceutical composition. Such operation is called "steady state" or "tonic" operation and is characterized by a controlled constant rate of injection at a predetermined baseline level.
The tonic mode of operation may be disrupted and the baseline level of administration supplemented with a pulse administration by manually instigating axial movement of subassembly 22 toward end 14 in the manner described above. Such movement exerts pressure on composition 12 and causes it to be discharged more rapidly. The magnitude and duration of the pulse will depend upon the extent to which the end cap is screwed into the housing. The length of the threads on the inner edge of the housing and/or shoulder 17 will limit the extent of axial movement of the subassembly. The supplemental pulse mode or "phasic" operation may be instigated one or more times depending upon the dosage regimen that is desired.
The components of the injector may be made from well known materials. The housing and end cap may be made from metals or plastics that are inert relative to the liquids they contact and are not irritating to the skin. Examples of such materials are stainless steel, aluminum, polyolefins such as polypropylene and polyethylene, polyesters, polyamides, and polycarbonates. The needle is preferably made of stainless steel and has a gauge in the range of 25 to 32. The support ring of the subassembly may be made from the same materials as are the housing and end cap. The semipermeable membrane of the subassembly may be made from cellulose esters and ethers, such as cellulose acetate and cellulose butyrate and other semipermeable film-forming compositions disclosed in U.S. Pat. No. 3,760,984 at col 4, line 53 to col 5, line 39 and in U.S. Pat. No. 3,995,631 at col 7, line 40 to col 8, line 15, which disclosures are incorporated herein by reference. Such materials may contain minor amounts of additives such as fillers, stabilizers, pigments, water flux enhancers, and water flux attenuators. The expandable bag of the subassembly may be made from impermeable materials such as latex rubber, polyisoprene, styrene-butadiene copolymers, butyl rubber, and nitrile rubber that are expandable by virtue of their elastomeric properties. Such elasticity may be facilitated by the formation of corrugations in the side walls of the bag. A less desirable alternative is to make the bag from an inelastic material that is rendered expandable by virtue of a bellows structure. The low friction washer that rests between the support ring and end cap may be made from materials such as polypropylene and polytetrafluoroethylene (sold under the trademark TEFLON®).
The pharmaceutical composition 25 must be in an injectable form such as a solution, dispersion, colloidal mixture, or low viscosity gel. It will normally be composed of an active pharmaceutical agent combined with a suitable diluent, typically a solvent for the agent. It may also contain minor amounts of innocuous additives such as stabilizers, viscosity modifiers, immunosuppressants, and the like. As used herein the term "pharmaceutical" is intended to include agents that have a pharmacological, physiological, or nutritional effect on the patient to which they are administered.
The water-imbibing agent that fills the expandable bag may be an osmotically effective agent (a compound that exhibits a relatively high osmotic pressure when in solution) such as the solutes disclosed in U.S. Pat. No. 4,034,756 at col 12, lines 55 to 61, which disclosure is incorporated herein by reference. Sodium chloride and potassium chloride are preferred solutes. Alternatively the water-imbibing agent may be a compound that is insoluble or partly soluble in water that is capable of absorbing water and swelling in response thereto to increase the volume, typically at least two fold. Examples of such compounds are disclosed in U.S. Pat. No. 4,180,073 at col. 4, lines 14 to 38 and U.S. Pat. No. 4,207,893 at col. 4, lines 23 to 47, which disclosures are incorporated herein by reference.
The aqueous liquid that is charged to compartment 24 is preferably water. Cosolvents that are also capable of diffusing through the semipermeable membrane may be admixed with the water if desired. Minor amounts of additives that do not elevate the osmotic pressure of the liquid significantly may also be included in the liquid.
FIG. 4 shows an embodiment of the injector, generally designated 45. Injector 45 includes a hollow cylindrical housing 46 that has an integral end wall 47 that defines the basal surface of the injector. The inner cylindrical surface of the housing has a shoulder 48 near the end wall, a threaded segment 49 located about midway on the surface, and a way 52 located near the edge of the open end of the housing. A needle 53 extends through the end wall and opens into the lumen of the housing. It has the same function and structure as needle 19 of injector 11. Within the housing lumen a 3-layer subassembly composed of an elastic impermeable membrane 54, a disc of water-imbibing material 55, and a rigid semipermeable membrane 56 is supported on shoulder 48. These components of the subassembly have the same composition and function as wall 37, composition 38, and membrane 39, respectively, of injector 11. An externally threaded locking ring 57 is received in the threaded segment 49 to compressively fix the edge of the subassembly.
The subassembly divides the housing lumen into two compartments: one, designated 58, contiguous to the elastic membrane and the other, designated 59, contiguous to the semipermeable membrane. Compartment 58 holds a pharmaceutical composition 62 that may be charged thereto before the subassembly is placed into the housing or thereafter by injection through opening 63 and septum 64 located in wall 47. Compartment 59 holds an aqueous liquid 65 that may be charged thereto after the subassembly is placed into the housing or thereafter by injection through an opening 66 and a septum 67 in end cap 68. The end cap has a splay 69 at the lower edge of its cylindrical surface that snap fits into way 52 to cap the open end of the housing.
Injector 45 operates in a manner similar to injector 11 with a few significant variations. Water from the aqueous liquid is imbibed through the semipermeable membrane by the water-imbibing composition 55. Since impermeable membrane 54 is in the form of a sheet rather than a bag, the influx of water into the space between it and the semipermeable membrane causes it to inflate arcuately (shown in phantom in FIG. 4) rather than expand linearly as does bag 37. The inflation or bowing of the membrane displaces pharmaceutical composition from the injector via the needle. Such displacement is at a substantially constant rate in accordance with the discussion of the operation of injector 11, supra. Unlike injector 11, however, phasic operation of injector 45 is not achieved by moving the subassembly axially. In this regard the end cap and subassembly of injector 45 are fixed and are not moveable axially except for disassembly purposes. Instead, phasic operation is effected by means of a radial opening 70 in the sidewall of the housing that opens into compartment 58 and a manually operable piston 71 that fits into opening 70. By depressing the piston inwardly, pressure is exerted on the pharmaceutical composition causing its rate of discharge from the injector to increase. The inclusion of opening 70 and piston 71 in injector 45 is optional. Without them the injector is capable of only tonic operation.
FIG. 5 illustrates another embodiment, designated 72, that is capable of both tonic and phasic operation. Housing 73 of the injector has a threaded segment 74 on the open end edge of its outer cylindrical surface and a needle 75 extending through its integral end wall 76. An axially slideable water-imbibing subassembly 77 is received in the housing lumen and is integrally connected to an interior threaded end cap 78 by an axial rib 79. Subassembly 77 divides the housing lumen into a pharmaceutical composition-containing compartment 82 contiguous to the end wall and an aqueous liquid-containing compartment 83 contiguous to the end cap. An O-ring 84 carried in a channel on the outer side of the subassembly forms a seal between the two compartments.
Subassembly 77 is composed of a cylindrical inverted cup-shaped support member 85 having a cylindrical sidewall 86 and an integral end wall 87 that has a pair of axial holes 88 in it. The inner surface of the side wall has a shoulder 89 on which a semipermeable membrane 92, a porous membrane support 93, and a flexible impermeable bag 94 containing a water-imbibing composition 95 are carried. A locking ring 96 compresses the edge of the membrane-support-bag combination against the shoulder and is fused or otherwise affixed to the inner surface of wall 86.
Injector 72 operates in the following manner. Starting with the injector disassembled, the pharmaceutical composition is placed into the housing, the subassembly is inserted into the housing, and the end cap is partly threaded onto the open end of the housing. Compartment 83, which is defined by the space within the support member above the semipermeable membrane, the axial holes in the end wall of the support member, and the space between the support member end wall and the end cap, is filled with the aqueous liquid via either of a pair of septum blocked vents 97 in the end cap. The injector is then placed on the skin. Water is imbibed from compartment 83 through the semipermeable membrane and underlying support into the flexible bag, causing the bag to expand into compartment 82 and displace the pharmaceutical composition therefrom via the needle at a constant rate. Phasic operation is effected simply by threading the end cap further onto the housing. This action forces the subassembly of the injector toward wall 76 because the end cap and subassembly are connected integrally by rib 79. The resulting increased pressure on the pharmaceutical composition causes it to flow from the injector at an increased rate.
FIG. 6 describes another embodiment, generally designated 98, that provides tonic and phasic injection. Its cylindrical housing 99 has threads 102 on the exterior upper edge of its cylindrical side wall 103 and a needle 104 extending through its basal end wall 105. The housing also has a septum blocked radial opening 106 through its side wall and a inner shoulder 107. A fixed water-imbibing subassembly 108 is compressively seated on the shoulder by means of a locking ring 109. Subassembly 108 consists of a support disc 112 that is sandwiched between a semipermeable membrane 113 and an expandable impermeable bag 114 that contains a water-imbibing composition 115. As in the above described embodiments, the subassembly divides the housing lumen into a pharmaceutical composition-containing compartment 116 and an aqueous liquid-containing compartment 117. The support disc has a series of spaced axial openings 118 that are covered on one side by the semipermeable membrane and open on the other side into the expandable bag and a large axial central opening 119 that is defined by an integral axially elongated collar 122. The central opening opens on one side into the water-containing compartment and on the other side into the expandable bag. An internally threaded end cap 123 is threaded into the open end of the housing. The end cap has an integral piston member 124 extending from the center of the inner side of its top wall axially into the collar of the support disc of the subassembly. An O-ring 125 carried on the cylindrical surface of the piston member forms a fluid tight, axially slideable seal between the piston member and the collar. The end cap also has a septum blocked vent 126 that extends through its top wall to compartment 117.
Injector 106 is filled and operates as follows. A liquid pharmaceutical composition 127 is injected into compartment 116 via opening 106, water 128 is injected into compartment 117 via vent 126, and the injector is placed on the skin. Water from compartment 117 is imbibed by composition 115 through the semipermeable membrane and axial openings in the support disc into the expandable bag. This influx of water causes the bag to expand into the pharmaceutical composition-containing compartment thereby displacing the pharmaceutical from the injector at a constant rate.
Phasic operation of the injector is effected by screwing the end cap further onto the housing. This action drives piston member 124 down into the collar thereby exerting pressure on composition 115. This pressure is equalized by expansion of the expandable bag which, in turn, increases the rate of displacement of the pharmaceutical composition from the injector. Such operation is distinct from that of the previously described injectors in that it is effected by exerting force on the contents of the expandable bag rather than by axial movement of the entire water-imbibing subassembly.
The components of the injectors depicted in FIGS. 4-6 may be made from the same materials as are the corresponding parts of the injector shown in FIGS. 1-3.
Modifications of the above-described injectors that are apparent to those of skill in the mechanical and/or medical device arts are intended to be within the scope of the following claims.
Patent | Priority | Assignee | Title |
10080846, | Dec 16 2009 | Becton, Dickinson and Company | Self-injection device |
10130759, | Mar 09 2012 | Picolife Technologies, LLC | Multi-ported drug delivery device having multi-reservoir cartridge system |
10195340, | Dec 16 2009 | Becton, Dickinson and Company | Self-injection device |
10213549, | Dec 01 2011 | Picolife Technologies, LLC | Drug delivery device and methods therefor |
10245420, | Jun 26 2012 | PicoLife Technologies | Medicament distribution systems and related methods of use |
10357610, | Dec 16 2009 | Becton, Dickinson and Company | Self-injection device |
10420881, | Dec 16 2009 | Becton, Dickinson and Company | Self-injection device |
10493199, | Mar 30 2006 | MannKind Corporation | Multi-cartridge fluid delivery device |
10525194, | Apr 23 2003 | MannKind Corporation | Hydraulically actuated pump for fluid administration |
10525246, | Dec 22 2006 | NANOMED SKINCARE, INC. | Microdevice and method for transdermal delivery and sampling of active substances |
10589023, | Jul 22 2003 | Becton, Dickinson and Company | Patch-like infusion device |
10610640, | Nov 30 2000 | ZEALAND PHARMA A S | Fluid delivery and measurement systems and methods |
10967123, | Dec 16 2009 | Becton, Dickinson and Company | Self-injection device |
11007316, | Dec 16 2009 | Becton, Dickinson and Company | Self-injection device |
11642456, | Apr 23 2003 | MannKind Corporation | Hydraulically actuated pump for fluid administration |
4474575, | Feb 01 1982 | ALZA CORPORATION, A CORP OF CA | Self-driven pump assembly and method of operation |
4505702, | Dec 23 1982 | ALZA Corporation | Manually operable rotary syringe |
4539004, | Feb 01 1982 | ALZA Corporation | Self-driven pump assembly and method of operation |
4552561, | Dec 23 1982 | ALZA Corporation | Body mounted pump housing and pump assembly employing the same |
4753651, | Aug 30 1982 | ALZA CORPORATION A CORP OF CA | Self-driven pump |
4886499, | Dec 18 1986 | Hoffman-La Roche Inc | Portable injection appliance |
4886514, | May 02 1985 | CARDINAL HEALTH 303, INC | Electrochemically driven drug dispenser |
4902278, | Feb 18 1987 | CARDINAL HEALTH 303, INC | Fluid delivery micropump |
5169390, | May 21 1990 | Pharmetrix Corporation | Osmotic infusion device |
5827530, | Feb 05 1996 | Fillable patch for dermal or transdermal delivery | |
5957895, | Feb 20 1998 | Becton, Dickinson and Company | Low-profile automatic injection device with self-emptying reservoir |
5983136, | Sep 17 1996 | DEKA Products Limited Partnership | System for delivery of drugs by transport |
6050988, | Dec 11 1997 | ALZA Corporation | Device for enhancing transdermal agent flux |
6083196, | Dec 11 1997 | ALZA Corporation | Device for enhancing transdermal agent flux |
6183434, | Jul 03 1996 | Nitto Denko Corporation | Multiple mechanical microporation of skin or mucosa |
6219574, | Jun 17 1997 | ALZA Corporation | Device and method for enchancing transdermal sampling |
6322808, | Dec 09 1998 | ALZA Corporation | Device for enhancing transdermal agent flux |
6527716, | Dec 30 1997 | Nitto Denko Corporation | Microporation of tissue for delivery of bioactive agents |
6918901, | Dec 10 1997 | Device and method for enhancing transdermal agent flux | |
6939324, | Nov 30 2000 | ZEALAND PHARMA A S | Fluid delivery and measurement systems and methods |
6953589, | Dec 11 1997 | ALZA Corporation | Device for enhancing transdermal agent flux |
6977074, | Jul 10 1997 | MannKind Corporation | Method of inducing a CTL response |
6979316, | May 23 2002 | Seedlings Life Science Ventures, LLC | Apparatus and method for rapid auto-injection of medication |
6994851, | Jul 07 1997 | MannKind Corporation | Method of inducing a CTL response |
7014625, | Oct 07 2002 | Novo Nordisk A S | Needle insertion device |
7103977, | Aug 21 2002 | Eveready Battery Company, Inc. | Razor having a microfluidic shaving aid delivery system and method of ejecting shaving aid |
7184826, | Jun 18 1996 | ALZA Corporation | Device and method for enhancing transdermal flux of agents being delivered or sampled |
7214221, | Mar 26 2002 | Becton, Dickinson and Company | Multi-stage fluid delivery device and method |
7250037, | Jul 22 2002 | Becton, Dickinson and Company | Patch-like infusion device |
7252651, | Jan 07 2003 | Becton Dickinson and Company | Disposable injection device |
7364729, | Jul 10 1997 | MannKind Corporation | Method of inducing a CTL response |
7481792, | Nov 30 2000 | ZEALAND PHARMA A S | Fluid delivery and measurement systems and methods |
7544185, | Oct 07 2002 | Novo Nordisk A S | Needle device comprising a plurality of needles |
7591806, | May 18 2004 | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances | |
7628770, | May 08 2003 | Novo Nordisk A S | Pivotable needle unit |
7637891, | Sep 12 2002 | Children's Hospital Medical Center; CHILDREN S HOSPITAL MEDICAL CENTER | Method and device for painless injection of medication |
7658724, | May 23 2002 | Seedings Life Science Ventures LLC | Apparatus and method for rapid auto-injection of medication |
7670314, | Feb 17 2004 | Children's Hospital Medical Center; CHILDREN S HOSPITAL MEDICAL CENTER | Injection device for administering a vaccine |
7678079, | Jul 22 2002 | Becton, Dickinson and Company | Patch-like infusion device |
7758561, | Dec 30 1997 | PASSPORT TECHNOLOGIES, INC | Microporation of tissue for delivery of bioactive agents |
7780636, | Jul 08 2003 | Novo Nordisk A S | Portable drug delivery device having an encapsulated needle |
7857131, | Aug 12 2003 | Becton, Dickinson and Company | Patch-like infusion device |
7896837, | Apr 02 2002 | Becton, Dickinson and Company | Method and device for intradermally delivering a substance |
7896841, | Feb 17 2004 | Children's Hospital Medical Center; CHILDREN S HOSPITAL MEDICAL CENTER | Injection device for administering a vaccine |
7905866, | Jan 07 2003 | Becton, Dickinson and Company | Disposable injection device |
7922462, | Mar 30 2004 | Novo Nordisk A S | Actuator system comprising lever mechanism |
7955297, | Aug 01 2003 | Novo Nordisk A S | Retraction means for transcutaneous device |
7981085, | May 08 2003 | Novo Nordisk A S | Internal needle inserter |
8016811, | Oct 24 2003 | PASSPORT TECHNOLOGIES, INC | Method for transdermal delivery of permeant substances |
8029469, | May 08 2003 | Novo Nordisk A S | External inserter for transcutaneous device |
8043250, | May 18 2005 | NANOMED DEVICES, INC | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
8048017, | May 18 2005 | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances | |
8062253, | Oct 27 2003 | Novo Nordisk A S | Medical skin mountable device |
8070726, | Apr 23 2003 | MannKind Corporation | Hydraulically actuated pump for long duration medicament administration |
8116860, | Mar 11 2002 | PASSPORT TECHNOLOGIES, INC | Transdermal porator and patch system and method for using same |
8157768, | Jan 07 2003 | Becton Dickinson and Company | Disposable injection device |
8167841, | Jan 24 2005 | Novo Nordisk A S | Transcutaneous device assembly |
8298172, | Apr 13 2005 | Novo Nordisk A S | Medical skin mountable device and system |
8361053, | Mar 30 2006 | MannKind Corporation | Multi-cartridge fluid delivery device |
8372393, | Jul 10 1997 | MannKind Corporation | Method of inducing a CTL response |
8394060, | Oct 17 2005 | Novo Nordisk A/S | Vented drug reservoir unit |
8430848, | Aug 13 2010 | Reservoir and administration device with ratcheting mechanism | |
8444604, | Aug 12 2003 | Becton, Dickinson and Company | Patch-like infusion device |
8512287, | Jul 22 2003 | Becton, Dickinson and Company | Patch-like infusion device |
8517958, | Jun 08 2000 | PASSPORT TECHNOLOGIES, INC | Transdermal integrated actuator device, methods of making and using same |
8557179, | Oct 31 2007 | Novo Nordisk A S | Non-porous material as sterilization barrier |
8585677, | Sep 21 2010 | Brigham Young University | Laminar injection apparatus and method |
8603040, | Jan 07 2003 | Becton, Dickinson and Company | Disposable injection device |
8641689, | Mar 11 2002 | PASSPORT TECHNOLOGIES, INC | Transdermal porator and patch system and method for using same |
8663538, | Feb 12 2009 | Picolife Technologies, LLC | Method of making a membrane for use with a flow control system for a micropump |
8667996, | May 04 2009 | MannKind Corporation | Fluid transfer device |
8706210, | Mar 11 2002 | PASSPORT TECHNOLOGIES, INC | Transdermal integrated actuator device, methods of making and using same |
8740851, | May 16 2003 | Novo Nordisk A/S | Integrated package |
8747363, | Apr 13 2005 | Medical skin mountable device and system | |
8758308, | Mar 16 2006 | CALIBRA MEDICAL, INC | Infusion device pump |
8771229, | Dec 01 2011 | Picolife Technologies, LLC | Cartridge system for delivery of medicament |
8790307, | Dec 01 2011 | Picolife Technologies, LLC | Drug delivery device and methods therefor |
8807169, | Feb 12 2009 | Picolife Technologies, LLC | Flow control system for a micropump |
8821443, | Mar 30 2006 | MannKind Corporation | Multi-cartridge fluid delivery device |
8858511, | Nov 30 2000 | MannKind Corporation | Fluid delivery and measurement systems and methods |
8945071, | Sep 02 2010 | Becton, Dickinson and Company | Self-injection device having needle cover with activation preventer |
8961469, | Dec 16 2009 | Becton, Dickinson and Company | Self-injection device |
8992478, | Nov 30 2000 | ZEALAND PHARMA A S | Fluid delivery and measurement systems and methods |
9033950, | Oct 24 2003 | PASSPORT TECHNOLOGIES, INC | Method for transdermal delivery of permeant substances |
9072828, | Apr 23 2003 | MannKind Corporation | Hydraulically actuated pump for long duration medicament administration |
9089636, | Jul 02 2004 | MannKind Corporation | Methods and devices for delivering GLP-1 and uses thereof |
9125983, | Apr 23 2003 | MannKind Corporation | Hydraulically actuated pump for fluid administration |
9168364, | Nov 04 2008 | JANISYS LIMITED | Transfer device for transferring a substance between the device and a subject |
9173992, | Mar 13 2006 | Novo Nordisk A S | Secure pairing of electronic devices using dual means of communication |
9364606, | Aug 12 2003 | Becton, Dickinson and Company | Patch-like infusion device |
9376224, | May 04 2009 | MannKind Corporation | Fluid transfer device |
9399094, | Jun 06 2006 | Novo Nordisk A S | Assembly comprising skin-mountable device and packaging therefore |
9447781, | Jul 22 2005 | University of Utah Research Foundation | Osmotically driven dispense pump and related components for use in high pressure applications |
9486616, | Mar 11 2002 | PASSPORT TECHNOLOGIES, INC | Transdermal integrated actuator device, methods of making and using same |
9511187, | Apr 23 2003 | MannKind Corporation | Hydraulically actuated pump for fluid administration |
9555187, | Dec 16 2009 | Becton, Dickinson and Company | Self-injection device |
9579380, | Dec 31 1996 | PASSPORT TECHNOLOGIES, INC | Microporation of tissue for delivery of bioactive agents |
9579461, | Dec 16 2009 | Becton, Dickinson and Company | Self-injection device |
9592336, | Oct 27 2003 | Novo Nordisk A/S | Medical skin mountable device |
9597450, | Jul 22 2003 | Becton, Dickinson and Company | Patch-like infusion device |
9636451, | Nov 30 2000 | ZEALAND PHARMA A S | Fluid delivery and measurement systems and methods |
9675752, | Sep 02 2010 | Becton, Dickinson and Company | Self-injection device having needle cover with activation preventer |
9687599, | Mar 30 2006 | MannKind Corporation | Multi-cartridge fluid delivery device |
9717850, | Dec 16 2009 | Becton, Dickinson and Company | Self-injection device |
9833562, | Dec 16 2009 | Becton, Dickinson and Company | Self-injection device |
9883834, | Apr 16 2012 | PicoLife Technologies | Medication delivery device with multi-reservoir cartridge system and related methods of use |
9918665, | Jan 03 2014 | PASSPORT TECHNOLOGIES, INC | Transdermal porator and patch system and method for using same |
9919097, | Dec 16 2009 | Becton, Dickinson and Company | Self-injection device |
9981083, | Nov 30 2000 | ZEALAND PHARMA A S | Fluid delivery and measurement systems and methods |
9993592, | Dec 01 2011 | Picolife Technologies, LLC | Cartridge system for delivery of medicament |
9999724, | Aug 12 2003 | Becton, Dickinson and Company | Patch-like infusion device |
D281528, | Dec 23 1982 | ALZA CORPORATION, A CA CORP | Body mounted pump for dispensing medication |
Patent | Priority | Assignee | Title |
3604417, | |||
3814097, | |||
3964482, | May 17 1971 | ALZA Corporation | Drug delivery device |
3987790, | Oct 01 1975 | ALZA Corporation | Osmotically driven fluid dispenser |
4159720, | Nov 28 1977 | Infusion of liquids into tissue |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Mar 28 1981 | ALZA Corporation | (assignment on the face of the patent) | / | |||
Apr 21 1982 | ECKENHOFF, JAMES B | ALZA CORPORATION, A CORP OF CA | ASSIGNMENT OF ASSIGNORS INTEREST | 003989 | /0949 |
Date | Maintenance Fee Events |
Dec 16 1985 | M170: Payment of Maintenance Fee, 4th Year, PL 96-517. |
Dec 26 1989 | M171: Payment of Maintenance Fee, 8th Year, PL 96-517. |
Dec 22 1993 | M185: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
Jul 20 1985 | 4 years fee payment window open |
Jan 20 1986 | 6 months grace period start (w surcharge) |
Jul 20 1986 | patent expiry (for year 4) |
Jul 20 1988 | 2 years to revive unintentionally abandoned end. (for year 4) |
Jul 20 1989 | 8 years fee payment window open |
Jan 20 1990 | 6 months grace period start (w surcharge) |
Jul 20 1990 | patent expiry (for year 8) |
Jul 20 1992 | 2 years to revive unintentionally abandoned end. (for year 8) |
Jul 20 1993 | 12 years fee payment window open |
Jan 20 1994 | 6 months grace period start (w surcharge) |
Jul 20 1994 | patent expiry (for year 12) |
Jul 20 1996 | 2 years to revive unintentionally abandoned end. (for year 12) |